TL;DR: During its 2026 Investor Day, Cigna emphasized that it could maintain current margins as the industry transitions from rebates to fees. Between competitive pressure from the other members of the Big 3, employer sentiment headwinds, and the increasing importance of its specialty business, the PBM business seems somewhat diminished.
Key data: Cigna projects its Pharmacy Benefit Services business will generate about $140 billion in adjusted revenue and represent roughly 23% of enterprise adjusted earnings in 2026. The business serves 117 million pharmacy customers, processes about 2.1 billion adjusted pharmacy claims, and handles one in three U.S. prescriptions, according to the company’s Investor Day presentation.
Tailwinds: Cigna points to purchasing scale, pharmacy-network reach, clinical expertise, and new benefit designs as advantages. Over the past two-plus years, the company reported 30%+ revenue CAGR and client retention in the mid-to-high 90s. In Q&A, management described the 2027 selling season as its strongest in several years and said some wins were win-backs from smaller PBMs.
Headwinds: Cigna said the Inflation Reduction Act, most-favored-nation pricing, and biosimilars are compressing rebates and creating greater pricing volatility. The company also cited growing expectations from employers and patients for transparency and more predictable costs. Its presentation estimated that average industry rebates per member per month would decline in 2026 and 2027.
Signature: Evernorth’s rebate-free model is intended to apply negotiated discounts at the pharmacy counter, show clients more clearly where benefit dollars go, and compensate the PBM through transparent fees for services. Cigna says members can save up to 30% per month off list prices for brand-name prescriptions. It plans to move Cigna Healthcare fully insured clients to Signature in January 2027 and make it the standard offering in January 2028.
A Milliman analysis, coauthored by AJ Ally, modeled an approximately $1.25 per member per month time-value benefit for plan sponsors under a point of sale net-price model, assuming equivalent discounts. That is a potential selling point for upfront discounts, though the estimate depends on the study’s assumptions and is not specific to every employer plan.
Cigna’s Outlook: Cigna says Signature can maintain current Pharmacy Benefit Services margins as clients move from the traditional model. The company projects flat-to-4% adjusted earnings growth for the Pharmacy Benefit Services division from 2026 through 2030.
HTN’s Take: Cigna is positioning Pharmacy Benefit Services as a durable, scaled business rather than a major growth engine, and it plays a critical role in specialty pharmacy growth. We have two questions: First, is Cigna’s view of PBM margin durability in this brave new world overly rosy? Cigna, and for that matter, OptumRx and Caremark, have expressed confidence in the economics holding up in the transparent PBM era, but in a competitive market where the PBM business feeds the specialty pharmacy business, it’s not hard to imagine a situation where PBM margins get sacrificed for specialty margins. Second, how real is the competitive threat? Cigna’s scale and retention provide a strong starting point; but it’s hard to totally discount upstarts like Rightway winning business and attracting funding. During Q3 earnings, HTN will take note of how the Big 3 characterizes the selling season and whether the competitive threat is starting to materialize.
